What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.”In the company’s words, NCT04974008 on ClinicalTrials.gov
- Tested for
- Bone Cancer
- Main trialPhase 2
- “Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.”In the company’s words, NCT04974008 on ClinicalTrials.gov
Other drugs for Bone Cancer
- ElraglusibActuate Therapeutics Inc. · Phase 2
- 153Sm-DOTMPTelix Pharmaceuticals (Innovations) Pty Limited · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 21 Sep 2023 | Osteosarcoma Maintenance Therapy With OST31-164 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026